New Protein Kinase C Assay Kits

<%=company1%> announces the availability of new Protein Kinase C (PKC) Assay Kits, the latest additions to PanVera's line of homogeneous fluorescence polarization-based assays. The mix and read format of the assays makes them fast, easy, and ideal for signal transduction research and high-throughput drug discovery screening. Configured for use with either 96- and 384-well plates, or single tubes, the kits are available in 100- and 1000-assay sizes. The PKC Assay has been used with PKC isoforms alpha, beta, gamma, delta, and zeta.

The principle behind PanVera's PKC Assay is competition: a fluorescent phosphopeptide tracer and the nonfluorescent phosphopeptides generated during a PKC reaction compete for binding to an antiphosphoserine antibody. In a reaction mixture containing no phosphopeptide product, the fluorescent tracer is bound by the antibody and the emission signal is polarized. However, in a reaction mixture containing phosphopeptide product, the fluorescent tracer is displaced from the antibody and the emission signal becomes depolarized. Fluorescence polarization can be measured on high-throughput instruments or on PanVera's single-tube Beacon 2000 Fluorescence Polarization Instrument.

Other PanVera fluorescence polarization-based assays include Estrogen Receptor a & b Competitor Assays, and the Tyrosine Kinase Assay.

PanVera Corporation is a leader in providing pharmaceutical companies with innovative, high-quality products and services to assist in making drug selection and development more efficient and less costly. PanVera provides recombinant proteins, CoreHTS fluorescence polarization-based assays for high-throughput screening, and contract services in protein manufacturing, assay development and drug metabolite production.